PACIFIC Trial Paves Way for More Immunotherapy Advances in Stage III NSCLC
Published: Thursday, Oct 17, 2019
Anna Chalmers, MD
The non–small cell lung cancer (NSCLC) paradigm is evolving as researchers look to build on the momentum of the phase III PACIFIC trial, in which durvalumab (Imfinzi) improved survival in patients with stage III disease, said Anna Chalmers, MD.
... to read the full story